(QTRX) Quanterix - Ratings and Ratios
Protein Detection Platforms, Immunoassay Assays, Reagents, Instruments
QTRX EPS (Earnings per Share)
QTRX Revenue
Description: QTRX Quanterix
Quanterix Corporation is a life sciences company that develops and markets digital immunoassay platforms, advancing precision health for research and diagnostics globally. The companys product portfolio includes the HD-X, SR-X, and SP-X instruments, which enable protein detection and measurement of multiplex chemiluminescent immunoassays. These platforms cater to the life science research sector, primarily serving laboratories associated with academic and governmental research institutions, pharmaceutical, biotechnology, and contract research companies.
The companys focus areas include neurology, oncology, immunology, and inflammation, with a range of assays and contract research services offered, including sample testing, homebrew assay development, and custom assay development. Quanterixs revenue streams are generated through direct field sales, support organizations, and distributors or sales agents. Key performance indicators (KPIs) to monitor the companys progress include revenue growth rate, customer acquisition rate, and the number of assays and services offered.
From a financial perspective, Quanterixs market capitalization stands at $259.94M USD, indicating a relatively small-cap company. The absence of a price-to-earnings (P/E) ratio suggests that the company is not yet profitable. Return on Equity (RoE) is -15.11%, indicating a negative return on shareholder equity. To improve, Quanterix should focus on increasing revenue, reducing costs, and enhancing operational efficiency. Other relevant KPIs include the companys burn rate, cash reserves, and research and development (R&D) expenditure as a percentage of revenue.
To drive growth, Quanterix could consider expanding its product portfolio, increasing its sales and marketing efforts, and exploring new markets and applications for its digital immunoassay platforms. The companys ability to innovate and stay ahead of the competition will be crucial in determining its long-term success. Key metrics to track include the number of new product launches, partnerships, and collaborations, as well as the companys progress in penetrating new markets.
QTRX Stock Overview
| Market Cap in USD | 202m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2017-12-07 |
QTRX Stock Ratings
| Growth Rating | -85.2% |
| Fundamental | 25.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -67.8% |
| Analyst Rating | 3.75 of 5 |
QTRX Dividends
Currently no dividends paidQTRX Growth Ratios
| Growth Correlation 3m | -86.1% |
| Growth Correlation 12m | -91.9% |
| Growth Correlation 5y | -80.4% |
| CAGR 5y | -20.06% |
| CAGR/Max DD 3y | -0.24 |
| CAGR/Mean DD 3y | -0.75 |
| Sharpe Ratio 12m | -0.64 |
| Alpha | -79.29 |
| Beta | 0.986 |
| Volatility | 85.63% |
| Current Volume | 472.7k |
| Average Volume 20d | 542.1k |
| Stop Loss | 4.7 (-5.4%) |
| Signal | 1.45 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-70.5m TTM) > 0 and > 6% of Revenue (6% = 7.52m TTM) |
| FCFTA -0.10 (>2.0%) and ΔFCFTA -4.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 218.5% (prev 254.7%; Δ -36.28pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -29.6m > Net Income -70.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (38.9m) change vs 12m ago 1.45% (target <= -2.0% for YES) |
| Gross Margin 55.54% (prev 56.07%; Δ -0.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 31.87% (prev 31.32%; Δ 0.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -7.24
| (A) 0.73 = (Total Current Assets 322.1m - Total Current Liabilities 48.2m) / Total Assets 375.6m |
| (B) -1.39 = Retained Earnings (Balance) -520.6m / Total Assets 375.6m |
| warn (B) unusual magnitude: -1.39 — check mapping/units |
| (C) -0.14 = EBIT TTM -54.1m / Avg Total Assets 393.4m |
| (D) -6.27 = Book Value of Equity -521.5m / Total Liabilities 83.2m |
| Total Rating: -7.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.00
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin -30.73% = -7.50 |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda -0.84 = -2.50 |
| 6. ROIC - WACC -29.03% = -12.50 |
| 7. RoE -22.07% = -2.50 |
| 8. Rev. Trend 33.56% = 2.52 |
| 9. EPS Trend -0.17% = -0.01 |
What is the price of QTRX shares?
Over the past week, the price has changed by +9.96%, over one month by +8.75%, over three months by -19.45% and over the past year by -61.68%.
Is Quanterix a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of QTRX is around 3.27 USD . This means that QTRX is currently overvalued and has a potential downside of -34.21%.
Is QTRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the QTRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6 | 20.7% |
| Analysts Target Price | 6 | 20.7% |
| ValueRay Target Price | 3.8 | -24.1% |
Last update: 2025-09-05 04:57
QTRX Fundamental Data Overview
CCE Cash And Equivalents = 261.2m USD (Cash And Short Term Investments, last quarter)
P/S = 1.6088
P/B = 0.6919
Beta = 1.031
Revenue TTM = 125.4m USD
EBIT TTM = -54.1m USD
EBITDA TTM = -47.5m USD
Long Term Debt = 34.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 5.15m USD (from shortTermDebt, last quarter)
Debt = 40.1m USD (Calculated: Short Term 5.15m + Long Term 34.9m)
Net Debt = -97.4m USD (from netDebt column, last quarter)
Enterprise Value = -18.7m USD (202.4m + Debt 40.1m - CCE 261.2m)
Interest Coverage Ratio = unknown (Ebit TTM -54.1m / Interest Expense TTM 0.0)
FCF Yield = -205.9% (FCF TTM -38.5m / Enterprise Value -18.7m)
FCF Margin = -30.73% (FCF TTM -38.5m / Revenue TTM 125.4m)
Net Margin = -56.23% (Net Income TTM -70.5m / Revenue TTM 125.4m)
Gross Margin = 55.54% ((Revenue TTM 125.4m - Cost of Revenue TTM 55.7m) / Revenue TTM)
Tobins Q-Ratio = 0.04 (Enterprise Value -18.7m / Book Value Of Equity -521.5m)
Interest Expense / Debt = 30.90% (Interest Expense 12.4m / Debt 40.1m)
Taxrate = 21.0% (US default)
NOPAT = -54.1m (EBIT -54.1m, no tax applied on loss)
Current Ratio = 6.68 (Total Current Assets 322.1m / Total Current Liabilities 48.2m)
Debt / Equity = 0.14 (Debt 40.1m / last Quarter total Stockholder Equity 292.5m)
Debt / EBITDA = -0.84 (Net Debt -97.4m / EBITDA -47.5m)
Debt / FCF = -1.04 (Debt 40.1m / FCF TTM -38.5m)
Total Stockholder Equity = 319.4m (last 4 quarters mean)
RoA = -18.77% (Net Income -70.5m, Total Assets 375.6m )
RoE = -22.07% (Net Income TTM -70.5m / Total Stockholder Equity 319.4m)
RoCE = -15.26% (Ebit -54.1m / (Equity 319.4m + L.T.Debt 34.9m))
RoIC = -16.93% (NOPAT -54.1m / Invested Capital 319.4m)
WACC = 12.09% (E(202.4m)/V(242.5m) * Re(9.65%)) + (D(40.1m)/V(242.5m) * Rd(30.90%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 0.45%
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -38.5m)
EPS Correlation: -0.17 | EPS CAGR: 0.0% | SUE: -3.25 | # QB: False
Revenue Correlation: 33.56 | Revenue CAGR: -2.67%
Additional Sources for QTRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle